Methocinamox, A Novel and Long-lasting Approach to Treating Opioid Abuse and Overdose
Dr. France will describe recent and ongoing studies in rodents and non-human primates to develop methocinamox (MCAM), a novel, pseudo-irreversible u-opioid receptor antagonist for the treatment of opioid use disorder and overdose. Dr. France will focus on interactions between MCAM and opioid self-administration, opioid dependence and withdrawal, opioid-induced respiratory depression, as well as the analgesic effects of opioids.